Speakers

Antonio Chiocca

Chairman, Department of Neurosurgery

Brigham and Women’s Hospital, Harvard Medical School

Austin Nuschke

Senior Medical Scientist, Solid Tumor Oncology

Amgen

Barbara Haertl

Associate Vice President, Manufacturing Operations

Calidi Biotherapeutics

Bart Spiesschart

Principal scientist In vivo Pharmacology

Boehringer Ingelhiem

Boris Minev

President, Medical & Scientific Affairs

Calidi Biotherapeutics

Di Yu

Head of Translational Research

Elicera Therapeutics

Enoch Yue

Associate Director, Business Development Oncology Search & Evaluation

Bristol Myers Squibb

Erik Digman Wiklund

Chief Executive Officer

Targovax

Francesca Barone

Chief Scientific Officer

Candel Therapeutics

James Burke

Chief Medical Officer

CG Oncology

Jeff Lange

Executive Vice President, Business Development

Virogin Biotech

Johanna Kaufmann

Executive Vice President, Oncology

Codagenix Inc.

John Bell

Senior Scientist

Ottawa Hospital Research Institute

John Goldberg

Chief Medical Officer

Oncorus Inc.

Kaja Jeyanthan

Analytical Development Scientist in Viral Development & Manufacturing Science

Turnstone Biologics

Karen Ann Cherkis

Senior Director Search & Evaluation

Bristol Myers Squibb

Muna Abdullahi

Researcher

Beacon Targeted Therapies

Natalia Ulyanova

Director Oncology Business Development, Search & Evaluation

Astellas

Neil Sheppard

Director & Head T Cell Engineering Lab

University of Pennsylvania Center for Cellular Immunotherapies

Patrik Erlmann

Head of Research Beyond Borders

Boehringer Ingelhiem

Paul Peter Tak

President & Chief Executive Officer

Candel Therapeutics

Robert Coffin

President & Chief R&D Officer

Replimune

Sari Pesonen

Chief Scientific Officer

Valo Therapeutics

Sharon Yavrom

Executive Director, Clinical Science

IMUGENE

Sheryl Tran

Senior Director Quality & Compliance

Vyriad

Stephen Russell

Chief Executive Officer

Vyriad, Inc.

Steve Thorne

Chief Scientific Officer

Kalivir Immunotheraputics